ORD 3577/2025

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
—
Action
Procedural application
Category
Case Management Orders
Parties: Claimants
Sanofi SA
Sanofi Winthrop Industrie
Sanofi-Aventis GmbH
Sanofi Belgium
Sanofi-Aventis Deutschland GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Reps: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)
Respondents
Accord Healthcare S.L.U.
Accord Healthcare GmbH
Accord Healthcare B.V.
Accord Healthcare Italia Srl
Accord Healthcare, Unipessoal Lda.
Accord Healthcare AB
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Dr Reddy's Srl
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Reps: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Louise Millot (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing); Elisabeth Greiner (df-mp)
Division: Munich LD
Judges: Matthias Zigann · Presiding judge and judge-rapporteur
Technology: Pharmaceutical & Medical
Language: —
First decided: Jan 22, 2025

Decisions

2025-01-22
Generic Order
The Munich Local Division issued a case-management order following a preliminary interim conference in Sanofi's infringement actions (four separate cases) against multiple generic-drug defendants (Accord, STADA, Dr. Reddy's, Zentiva), setting the value of infringement claims and counterclaims, directing Sanofi to remedy formal deficiencies in its pleadings, and waiving all other outstanding deadlines pending clarification.
Legal issues:Case management following preliminary interim conference under R. 105.5 RoPFormal requirements for statement of claimValuation of infringement claims and counterclaims for revocationAdditional court fees for infringement actions

Documents